Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/23/2023 | $3.00 → $2.00 | Neutral → Underperform | BofA Securities |
| 2/23/2023 | $3.00 | Overweight → Neutral | Cantor Fitzgerald |
| 2/23/2023 | Outperform → Market Perform | Cowen | |
| 1/25/2023 | Buy → Neutral | BTIG Research | |
| 1/18/2023 | $7.00 → $3.00 | Buy → Neutral | BofA Securities |
| 1/6/2023 | $11.00 → $2.00 | Outperform → Mkt Perform | SVB Leerink |
| 1/6/2023 | $14.00 → $7.00 | Outperform → Market Perform | BMO Capital Markets |
| 9/15/2022 | $12.00 | Overweight | Cantor Fitzgerald |
Special dividend estimated to be $1.03 per share Payment of special dividend conditioned upon closing of merger Graphite Bio, Inc. (NASDAQ:GRPH) ("Graphite" or the "Company") today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the "Merger") with Lenz Therapeutics, Inc. ("LENZ") pursuant to the Agreement and Plan of Merger, dated November 14, 2023 (the "Merger Agreement"). The special dividend, which the Company estimates will be $1.03 per share of Graphite's common stock, will be payable in cash to the stockholders of record as of March 18, 2024. The exact amount of the special dividend will be calculated afte
- Merger to create NASDAQ-listed, late clinical-stage biopharmaceutical company focused on advancing LENZ Therapeutics' lead assets for the treatment of presbyopia - Combined company expected to have approximately $225 million of cash or cash equivalents at close, including $53.5 million from a concurrent PIPE financing - Companies to host joint webcast today, November 15, 2023 at 8:00 a.m. ET LENZ Therapeutics, a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision, and Graphite Bio, Inc. (NASDAQ:GRPH) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock tran
Healthpeak Properties, Inc. (NYSE:PEAK), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced results for the third quarter ended September 30, 2023. THIRD QUARTER 2023 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS – Net income of $0.12 per share, Nareit FFO of $0.46 per share, FFO as Adjusted of $0.45 per share, AFFO of $0.40 per share, and blended Total Same-Store Portfolio Cash (Adjusted) NOI growth of 6.0% – Third quarter new and renewal lease executions totaled 2.3 million square feet: • Outpatient Medical new and renewal lease executions totaled 2.1 million square feet, an all-time quarterly high, including a 1.3 millio
Gainers Better Therapeutics (NASDAQ:BTTX) shares increased by 85.4% to $0.06 during Friday's pre-market session. The market value of their outstanding shares is at $3.5 million. Madrigal Pharmaceuticals (NASDAQ:MDGL) shares moved upwards by 22.34% to $298.0. The market value of their outstanding shares is at $5.9 billion. Akebia Therapeutics (NASDAQ:AKBA) stock rose 16.05% to $1.59. The market value of their outstanding shares is at $299.5 million. As per the press release, Q4 earnings came out yesterday. Rallybio (NASDAQ:RLYB) shares increased by 15.98% to $1.85. The company's market cap stands at $69.9 million. The company's, Q4 earnings came out 3 days ago. Avalo Therapeutics (NASDAQ
BofA Securities downgraded Graphite Bio from Neutral to Underperform and set a new price target of $2.00 from $3.00 previously
Cantor Fitzgerald downgraded Graphite Bio from Overweight to Neutral and set a new price target of $3.00
Cowen downgraded Graphite Bio from Outperform to Market Perform
4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)
4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)
424B3 - LENZ Therapeutics, Inc. (0001815776) (Filer)
10-Q - LENZ Therapeutics, Inc. (0001815776) (Filer)
8-K - LENZ Therapeutics, Inc. (0001815776) (Filer)
Special dividend estimated to be $1.03 per share Payment of special dividend conditioned upon closing of merger Graphite Bio, Inc. (NASDAQ:GRPH) ("Graphite" or the "Company") today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the "Merger") with Lenz Therapeutics, Inc. ("LENZ") pursuant to the Agreement and Plan of Merger, dated November 14, 2023 (the "Merger Agreement"). The special dividend, which the Company estimates will be $1.03 per share of Graphite's common stock, will be payable in cash to the stockholders of record as of March 18, 2024. The exact amount of the special dividend will be calculated afte
- Merger to create NASDAQ-listed, late clinical-stage biopharmaceutical company focused on advancing LENZ Therapeutics' lead assets for the treatment of presbyopia - Combined company expected to have approximately $225 million of cash or cash equivalents at close, including $53.5 million from a concurrent PIPE financing - Companies to host joint webcast today, November 15, 2023 at 8:00 a.m. ET LENZ Therapeutics, a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision, and Graphite Bio, Inc. (NASDAQ:GRPH) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock tran
Healthpeak Properties, Inc. (NYSE:PEAK), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced results for the third quarter ended September 30, 2023. THIRD QUARTER 2023 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS – Net income of $0.12 per share, Nareit FFO of $0.46 per share, FFO as Adjusted of $0.45 per share, AFFO of $0.40 per share, and blended Total Same-Store Portfolio Cash (Adjusted) NOI growth of 6.0% – Third quarter new and renewal lease executions totaled 2.3 million square feet: • Outpatient Medical new and renewal lease executions totaled 2.1 million square feet, an all-time quarterly high, including a 1.3 millio
Graphite Bio, Inc. (NASDAQ:GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced the appointment of Alethia Young as chief financial officer. Ms. Young joins Graphite Bio from Cantor Fitzgerald, where she served as senior biotech analyst and head of research, managing the equity research department covering small-cap, mid-cap and large-cap biotechnology companies. In this newly created position, Ms. Young will oversee the company's finance, investor relations and corporate communications functions, and will play a key role in overall corporate strategy. "On behalf of the e
SC 13G/A - LENZ Therapeutics, Inc. (0001815776) (Subject)
SC 13G - LENZ Therapeutics, Inc. (0001815776) (Subject)
SC 13D - LENZ Therapeutics, Inc. (0001815776) (Subject)
4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)
3 - LENZ Therapeutics, Inc. (0001815776) (Issuer)
4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)